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ABSTRACT  
Background: With low implementation of cost-effective health technologies being a problem in many health 
systems, it may be worth considering the potential effect of research on implementation at the time of 
technology appraisal. 
Objective: To demonstrate methods for assessing the value of research in terms of both reduction of 
uncertainty and improvement in implementation, considering the dynamic nature of implementation. 
Methods: We extend an existing framework to assess the values of information and implementation to account 
for the relationship between information and implementation and to reflect implementation dynamics. The 
resulting framework is applied to a genuine technology in the area of pre-term birth screening and results 
obtained from static and dynamic analyses are compared. The data to inform the effect of research evidence 
on implementation dynamics was obtained through a previous elicitation of expert opinion on quantities that 
informed the parameterisation of a dynamic implementation curve based on diffusion theory. 
Results: Incorporating the relationship between information and implementation in the assessment of research 
led to an expected value of research much larger than the one based on reduction of uncertainty alone in the 
exemplar case study. Considering the dynamics of implementation makes a significant difference to the 
expected value of research and accounting for the time when research reports may do so as well, both making 
existing analyses more realistic. However, such analyses require additional data and therefore resources.  
Conclusions: Assessing the expected value of research in terms of both, the reduction in uncertainty and 
improvements in implementation dynamics, has the potential to complement currently used analyses in health 
technology assessments, especially in Recommendation with Research decision.  
 
Key words: Value of information, Diffusion of innovation  
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Background 
Implementation of health technologies has often been noted to be low in many OECD countries (OECD 
Health Project, 2005) and also especially in the UK (Department of Health, 2011), leading to inefficiencies in 
the health system caused by the co-existence and reimbursement of cost-effective and cost-ineffective 
technologies. These inefficiencies pose a burden to the payer in terms of money lost that could be spent in a 
more effective way elsewhere, and ultimately to patients in terms of health lost. The NHS has therefore 
declared getting cost-effective technologies into practice a priority (Department of Health, 2011). Despite this, 
there is no standardised procedure in place in the UK that allows evaluating implementation measures at the 
time of technology appraisals (NICE, 2013). In fact, NICE does not have a mandate to recommend 
implementation measures, but it can recommend that further research be conducted, if there is large decision 
uncertainty (NICE, 2013).  
Such Recommendation with Research (RwR) or Only in Research (OIR) decisions can be considered using 
the framework on coverage decisions developed by Walker et al. (2012) and can be assessed for their value 
using Expected Value of Information (EVI) methods. However, to our knowledge, the EVI methods used in 
practice do not consider the effect that the recommended research studies may have on the dynamics of health 
technology implementation. This is an omission, as further evidence may very well influence the 
implementation of a new health technology (Fenwick et al., 2008), thus reducing the burden that low 
implementation poses to the payer. 
While research can already be designed to address the decision uncertainty present in appraisals, research 
could also be designed to improve implementation, as was identified by Fenwick et al. (2008) and investigated 
further by Willan and Eckermann (2010). These two objectives may or may not be reached by similar research 
studies and a methodology is required that can assist the design of research studies such that the maximum 
impact on the burdens of low implementation and uncertainty can be achieved. One possible question that 
may arise is which research objective to address. EVI analysis may highlight different drivers of decision 
uncertainty that may differ from the clinical uncertainty that may drive the adoption decision.   
A second omission lies in the fact that when implementation strategies were evaluated in the past, they did 
not, to our knowledge, consider the dynamic nature of implementation. Instead, assumptions were made 
around the future level of implementation that could be achieved when investment in implementation 
measures was made (Hoomans et al., 2009, Walker et al., 2014) or future implementation levels were fitted 
using simple regression methods without any link to existing diffusion theory by Rogers (2003), as was done 
in Whyte et al. (2014). This future maximum achievable implementation would then be compared to the level 
of implementation that was observed or estimated at the time, as for example in the application of the 
expected value of implementation framework by Hoomans et al. (2009), without considering any changes in 
implementation that might occur naturally. 
One reason for these omissions may be methodological issues: the estimation of potentially low and changing 
implementation in the future can be challenging, especially when the technology has not been introduced yet 
(Serra-Sastre and McGuire, 2009); and effects of any implementation measures, including research, on 
implementation are equally as difficult to predict.  
The aim of this research was to propose a framework that facilitates understanding of the role of research 
studies for their potential in reducing the burdens of uncertainty and low implementation, using elicited data 
on implementation dynamics for the pre- and post-research implementation estimates.  
This article is structured as follows: in the next section, the concepts needed for the evaluation of 
implementation measures and research are described and then, the concepts are extended to incorporate the 
dynamic nature of implementation. Following that, static and dynamic expected value of research analysis 
will be illustrated in an anonymised genuine case study in pre-term birth screening. Lastly, results and 
implications will be discussed. 
 
Concepts for assessing the Expected Value of Research  
We first describe the existing Expected Value (EV) concepts and then describe how we extended them. All of 
these concepts are summarised in Table 1. We show the mathematical expression for each of the value 
concepts in the technical appendix. 
 
Existing concepts for evaluating research and implementation 
The Expected Value of Perfect Information (EVPI) is the expected value of reducing all uncertainty about 
parameters present in a decision (Briggs et al., 2006). When a decision is made under uncertainty, because we 
GRQRWKDYHSHUIHFWLQIRUPDWLRQDERXWSDUDPHWHUVWKHUHLVDULVNRIPDNLQJWKH³ZURQJ´GHFLVLRQWKDWLV
recommending a health technology that does not provide the maximum expected net benefit (in monetary or 
health terms). The cost of making this decision under uncertainty, the EVPI, is therefore composed of the risk 
RIPDNLQJWKH³ZURQJ´GHFLVLRQDQGWKHFRQVHTXHQFHVRIPDNLQJWKDWGHFLVLRQLQWHUPVRIFRVWVRUKHDOWK
foregone.  
With implementation being less than perfect, the expected value of achieving full implementation is of 
interest. This has been referred to as the Expected Value of Perfect Implementation (EVPIM) (Fenwick et al., 
2008). The EVPIM reflects the losses that the payer will incur due to less cost-effective technologies 
remaining partially implemented. If the EVPIM is not resolved, that is, full implementation is not achieved, 
the payer will pay for a mix of technologies that is in use that does not maximise the health gain associated 
with the spending or that does not minimise the cost associated with the health gain.  
When there is a burden associated with both, decision uncertainty and low implementation, the payer faces a 
combined burden of uncertainty and compliance to the recommendation decision that is described by the 
Expected Value of Perfection (EVP). Decision uncertainty, measured by the EVPI, can be reduced by 
conducting further research. When there is low implementation of the cost-effective technology, this can be 
addressed by investing in implementation measures, thus decreasing the EVPIM. The Expected Value of 
Perfection can therefore be reduced by implementation measures and research.  
It follows that when perfect implementation has been achieved, the Expected Value of Perfection reduces to 
the EVPI. When perfect information has been achieved, the EVP could reduce to the EV of Perfect 
Implementation, assuming that research and implementation are completely independent. In reality, however, 
effects of research on implementation may result in a reduction in the EVPIM without having executed any 
implementation measures. This could be called the post-research EVPIM and it is lower than the pre-research 
EVPIM if research has an effect on implementation. This means that there is a part of the Expected Value of 
Perfection (and equally the EVPIM) that can be addressed by research activities that tackle both 
implementation and decision uncertainty at the same time. This part of the EVP is the realisable EVPI 
(rEVPI) that was described by Fenwick et al. (2008).  
Of practical importance, the distinction of the post-research EVPIM and the rEVPI implies that part of the 
EVPIM can only be resolved through research. The value of research can therefore be much larger than the 
EVPI alone. To aid decision-making in terms of improving implementation and reducing uncertainty, it is 
useful to present the EVP as the sum of the EVPI, the post-research EVPIM and the rEVPI.  
Other concepts that are useful in the context of assessing research studies are the expected value of perfect 
parameter information (EVPPI), that determines how much individual or grouped input parameters contribute 
to decision uncertainty, and the realisable EVPPI (rEVPPI), that determines the value of resolving all 
uncertainty associated with individual or grouped parameters in terms of reducing uncertainty and improving 
implementation.  
 
The Expected Value of Research 
A specific research study can be evaluated using the Expected Value of Sample Information (EVSI). The EVSI 
indicates by how much the EVPI will be reduced when further research is conducted.  
When implementation is imperfect, the EVSI can be adjusted by implementation, and implementation levels 
can assume different values before and after the research has been conducted. The resulting EVSI is thus the 
Expected Value of Specific Implementation Measures (EVSIM) of the planned research study as the effect of 
that research will only manifest itself in improved implementation (or worsened implementation) rather than 
full adoption. The EV of Perfect Implementation will then be reduced by the EVSIM of the research.  
The Expected Value of Research (EVR) in terms of both the reduction of uncertainty and the change in 
implementation is then the sum of the EVSIM and the EVSI because research affects both the EVPI and the 
EVPIM.  
The various concepts defined above are summarised in Table 1. 
 
Table 1. Value concepts relating to decision uncertainty and imperfect implementation 
 Value concept Description 
U
n
ce
rt
a
in
ty
 
EVPI The value of resolving all decision uncertainty 
EVPPI 
The value of resolving all uncertainty related to individual or 
grouped model parameters 
EVSI 
The value of a proposed research study design in reducing 
uncertainty  
Im
pl
em
en
ta
tio
n
 
EVPIM  
The value of achieving perfect implementation (from current 
³EDVHOLQH´OHYHO 
rEVPI 
The value of improving implementation by resolving all 
decision uncertainty 
rEVPPI 
The value of improving implementation by resolving all 
uncertainty caused by individual or grouped model parameters 
EVSIM 
The value of improving implementation with a proposed  
implementation measure or research study design 
Bo
th
 
EVP 
The value of achieving perfect implementation and resolving 
all decision uncertainty 
EVR 
The value of a proposed research study design in improving 
implementation and reducing uncertainty  
 
 
Accruing the Expected Value of Research over the population and time horizon 
The previous section described the concepts related to the Expected Value of Research on a per-person level. 
To obtain an idea of the Expected Value of Perfection to the England population and over the time horizon for 
which the decision will remain relevant, the affected patient population can be multiplied by the per person 
EVP in each year and the discounted annual population EVPs for each year summed up to the decision time 
horizon. 
When specific implementation measures or research studies are to be evaluated against their cost, their value 
will only accrue for the proportion of the population that can be reached with the cost-effective technology. 
This proportion of the population is the post-implementation measure implementation and it is multiplied by 
the affected population to obtain the EV of Specific Implementation Measures and the EV of Research for the 
England population. The annual discounted population EVSIM can then be summed over the time horizon the 
decision will remain relevant for. 
 
Incorporating implementation dynamics in the Expected Value of Research 
Making the defined value concepts dynamic 
The analyses described above do not take implementation dynamics, timings of research or implementation 
measures into account. In this section, we describe how the elicited implementation dynamics are used in the 
present framework and how effects of the timing of research and implementation measures are calculated. 
Taking implementation dynamics into account in the calculation of the EVP requires all measures that are 
functions of implementation to be adjusted for the proportion of the population receiving the technology in 
each year up to the time horizon at which the decision ceases to be relevant. This affects the rEVPI, the 
EVPIM, the rEVPPI and the EVSIM.  
The realisable EVPI can be calculated with the mix of technology use for each year. For example, if utilisation 
of intervention A was at 2% in the first year, then utilisation of comparators B and C would be at 49% each 
(assuming equal utilisation for the two remaining technologies, due to a lack of knowledge that suggests 
otherwise), and the rEVPI would be calculated according to that. In the second year, implementation of A 
might be at 10%, resulting in 45% of implementation of B and C, and so on. The dynamic rEVPI could be 
presented for every year, but to obtain an idea of the magnitude, the average rEVPI over the periods up to the 
time horizon is taken, with discounting of future periods accounted for.  
 
Accruing the dynamic EVR concepts over the population and time horizon 
The discounted population values for the EVPI, the rEVPI, the EVPIM and the rEVPPI will be calculated 
using the total of the affected patient population because the whole population will be affected by these 
burdens. However, the EV of Specific Implementation Measures and EV of Research measures would only 
accrue for those who will receive the technology with the largest expected net benefit.  
 It is important to highlight that the interpretation of the EVPI is only that of the maximum value of further 
research if implementation is also made perfect. If one wanted to know the maximum value of further research 
given that implementation remains unchanged at a low current level, the population EVPI should be adjusted 
by the achievable implementation.  
 
Assessing the residual Expected Value of Perfection after research 
The residual EVP after research studies are conducted can be calculated by subtracting the EVR associated 
with the planned research study from the EVP at the outset. For this evaluation, the population values 
aggregated over all periods until the time horizon should be used to reflect the value of the research to the 
payer. The research is then worth doing if the population EVR exceeds its cost.  
 
The timing of implementation measures and their effects  
When assessing the expected value of implementation measures in a dynamic analysis, the timing of the 
measure itself and its effects are crucial, as was highlighted by Claxton et al. (2011). For instance, if an 
implementation measure is a research study that takes two years to report from the time of decision-making, 
the existing EVPI will only be reduced at the time that a new decision is made based on that new research. 
The EVPIM may only be adjusted by the EVSIM much later, when implementation changes because of the 
new findings.  
The residual EVP that is left after the planned research studies have been conducted is therefore the sum of the 
EVP in the first periods until the research reports and a decision is taken ± and the sum of the post-research 
EVP over the remaining periods until the time horizon, where the post-research EVP results from subtracting 
the EVR from the pre-research EVP.  
 
The static and dynamic EVR frameworks applied in a case study  
The above framework was applied in a genuine but anonymised case study involving a new pre-term birth 
screening technology that is currently in development. We refer to the new technology as technology A and 
the comparators in the health economic model are technologies B and C, where technology C is No Screening. 
When patients are tested positive, they would undergo treatment that could help prevent a condition from 
developing. Three health states are possible outcomes of the model. The screening technologies, treatment and 
health states are associated with costs, and the health states are associated with utilities presented as quality-
adjusted life years (QALYs). The expected Incremental Cost-Effectiveness Ratios (ICERs) and net benefits 
were calculated using Probabilistic Sensitivity Analysis (PSA), based on 10,000 simulations. EVPPI values 
were generated using the Generalized Additive Model (GAM) regression method developed by Strong et al. 
(2014). 
Two research studies had been identified in a qualitative study to be relevant to the adoption decision of 
technology A (referred to as Study I and Study II in the following). Study I would study the predictive ability 
of technology A and study II the response to treatment after screening with technology A. The EVPPI analysis 
showed that the parameters are informed by these studies were also driving decision uncertainty.  
To facilitate assessing the EVR, information was needed on implementation estimates before and after these 
research studies were conducted. The dynamic estimates were obtained through an elicitation of expert 
opinions on parameters that inform an adaptation of the established model of technology diffusion (Bass, 
1969). The elicitation method we developed only requires elicitation of three quantities for any multi-period 
diffusion curve. For the static analysis, we used the estimate of the maximum attainable number of adoptions 
prior and posterior to conducting further research that we obtained from that elicitation study. Of course, this 
assumption of a sudden jump in implementation is not necessarily realistic, reflecting the general problem 
with the static analysis in the dynamic context of technology implementation.   
To calculate the EVSI, it was necessary to simulate the research that is planned. The process of trial data 
simulation has been described previously (Ades et al., 2004, Strong et al., 2015) and we followed the steps 
outlined there. Both research studies were designed to be one-arm observational studies, which could enable 
these studies to be conducted even after the technology is recommended. Statistical models for the data to be 
collected in both studies were specified, together with the sample size of 150 patients for each study and then 
DGDWDVHWIURPHDFKSURSRVHGVWXG\FRXOGEHVLPXODWHGIRUHDFKµURZ¶RIWKH36$RQWKHSDUDPHWHUVLQ
question. That is, for each draw from the joint distribution of the PSA, we generated a sample of data ݔሺ௞ሻ for 
those 150 patients, sampling from a binomial distribution for both research studies. A binomial model was 
chosen because both studies were investigating a sample proportion with a particular response. Given the 
simulated data, the implied model parameters for the decision model if only the new data would be used could 
be calculated. We calculated the EVSI values for both research studies using the GAM regression method 
developed by Strong et al. (2015). 
To calculate the EVSIM of both research studies with the reporting time of research accounted for, we 
assumed Study I to report within two years of the decision and Study II to report within three years of the 
recommendation decision and re-appraisal to happen at the time those studies report. In the years up to the 
time when the research reports (two and three years after the decision for Study I and II respectively), 
implementation would follow the baseline uptake curve and the respective curves for the two research studies. 
This jump is a simplification because the post-research curves were elicited under the assumption that those 
research results were available at the start of the implementation process.  
Results of the static EVR analysis applied in a case study  
Based on the probabilistic analysis, technology A is expected to be dominating against both technologies B 
and C, reflecting that it is cost-saving and providing a QALY gain. The PSA results in technology A being the 
technology with the highest expected net benefit (Table 2). All costs and QALYs are scaled to a per person 
level.  
  
Table 2. Model results 
Threshold: £20,000 / 
QALY 
A B C 
Expected Costs £18,958 £19,157 £19,331 
Expected QALYs 29.53 29.527 29.525 
ICER against CL scans Dominating - NA 
ICER against No 
screening 
Dominating Dominating - 
Expected Net Benefits £571,637 £571,386 £571,167 
 
The results presented in Table 2 are associated with some uncertainty as shown in Figure 1 and Figure 2. 
Fifteen percent of the joint distribution for the incremental net benefit and incremental cost, when comparing 
against technology B lie to the North West of the threshold diagonal. The results against technology C are 
more certain: Less than 1 % lie to the North West of the threshold diagonal. That is, we can be quite certain 
that technology A is cheaper and more effective than technology C. 
  
 
 
The above analyses showed that the per person EVPI is only £17 (see Table 3). However, accrued over the 
affected population in England and for a time horizon of ten years, further research could potentially be 
worthwhile if it reduced the uncertainty at costs that fell below the EVPI of £3 million. The EVPPI analysis 
Figure 1. Cost-effectiveness plane of A against B 
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Figure 2. Cost-effectiveness plane of A against C 
estimated that the parameters that would be informed by the identified research studies I and II explained 93% 
of the EVPI.  
The burden caused by low implementation was larger than the burden caused by uncertainty (Table 3). This is 
because implementation of the dominating technology A was low (at 30%) to start with. At a per person level, 
it would cost the payer £252, which over the population of affected patients over a time horizon of ten years 
amounts to almost £47 million (Table 3). A significant part of the EVPIM could be addressed through 
additional research because of the large realisable EVPI, £125 per person, which translates into almost £9 
million for England over a ten year time horizon, which describes the value of resolving uncertainty in terms 
of changing implementation. This suggests that it may be worth conducting additional research as a means of 
increasing implementation, thus reducing the burden to the payer of financing other cost-ineffective screening 
technologies.  
Together, the Expected Value of Perfection is £269 per person, or £50 million for the England population over 
ten years. The possible reduction in the EVP that can be achieved by resolving all uncertainty surrounding the 
parameters studied in Studies I and II has a value of approximately £7.8 per person or £1.5 million for the 
England population over ten years (see the rEVPPI in Table 3).  
However, the design of Studies I and II only allows the resolution of part of the EVPPI of the studied 
parameters. Research Study I has an EVR of approximately £6 per person, resulting in a reduction of the EVP 
by £1.11 million at a population level and over ten years. Research Study II has an EVR of approximately £3 
per person, reducing the EVP by £160,000. These EVSIM values are larger than the EVSI of the trials (£4 and 
£0 at a per person level, respectively), demonstrating that the value of the research studies relate mainly to 
their associated increase in implementation of the most cost-effective technology.  
 
  
Table 3. Static expected value of information and implementation results  
  Per 
person 
Population per 
annum (20,000 
patients affected) 
Population over time 
horizon of 10 years 
(discounted) 
U
n
ce
rt
a
in
ty
 
EVPI £17 £331,143 £3.08 million 
EVPPI (Parameters I) £4.07 £81,521 £759,500 
EVPPI (Parameters II) £0.01 £295 £2,753 
EVSI (Study I) £4.07 £81,526 £759,543 
EVSI (Study II) £0 £0 £0 
Im
pl
em
en
ta
tio
n
 
EVPIM  £252 £5.03 million £46.9 million 
rEVPI £47 £938,111 £8.74 million 
rEVPPI (Parameters I+II)  £7.8 £156,352 £1.46 million 
EVSIM (Study I)  £1.9 £37,524 £107,756 
EVSIM (Study II)  £2.8 £56,286 £162,996 
Bo
th
 
EVP £269 £5.4 million £50.1 million 
EVR (Study I) £5.97 £119,400 £1.11 million 
EVR (Study II) £2.8 £56,286 £162,996 
 
 
Figure 3. The EVP and the post-research residual EVPs 
 
 
The static EVP and possible reductions in it with the two research studies are presented in Figure 3. The 
proposed research studies only cause a relatively small reduction in the EVP because the gain in 
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implementation that can be achieved by those research studies is small. The difference in size of the EVR 
compared to the EVP is especially large when presented at the population level, because the EVR will only be 
accrued for those patients who receive technology A. It could be worthwhile conducting the proposed research 
studies if their cost fell below the expected value of research, which at the values presented here may not be 
likely. 
The static analysis indicates that further implementation measures are required in order to reduce the larger 
EVPIM but the calculation of the EVP and its reductions were based on static baseline implementation 
estimates that are unrealistic. Dynamic analysis is therefore required and the next section explores how results 
of the dynamic analysis compare to the results of the static analysis. 
Results of the dynamic EVR analysis  
When implementation dynamics are considered (Table 4), results only differ in terms of rEVPI, rEVPPI, 
EVPIM, EVP and EVSIM values but not EVPI and EVPPI. Figure 4 shows that the reduction in the EVP 
achievable with the designed research studies remains small. This is because both the EVPIM and the EVSIM 
have increased and the reduction in the EVP, that is the EVR of both research studies, remains just under 2% 
of the EVP. 
In this case study, results for all of the measures that are influenced by implementation from the dynamic 
analysis exceed those from the static analysis. The reason for this is illustrated through an example in Figure 5. 
In the static analysis, it was assumed that a favourable decision for technology A is followed by an immediate 
jump to the top of the baseline uptake curve, shown by the dashed grey line. Further research Studies I and II 
before the research recommendation would result in immediate implementation shown by the solid grey line 
in Figure 5.  
In contrast, and more realistically, a recommendation decision would trigger the much slower implementation 
process illustrated by the dashed blue line for no further research and the solid blue line for further research 
studies completed (Figure 5). It becomes evident from Figure 5 that the gap between the blue lines is much 
larger than between the grey lines, even when averaged over all periods. This leads to the dynamic analysis 
exhibiting larger values for the EVSIM associated with the different research strategies. This finding is not 
generalisable as it is dependent on the static before and after implementation values as well as the difference 
of the dynamic curves. What is generalisable is that results from the dynamic analysis will differ from the 
static analysis unless implementation can be truly described by a constant over time. 
  
Table 4. Dynamic expected value of perfection results  
  Per 
person 
Population per 
annum (20,000 
patients affected) 
Population over time 
horizon of 10 years 
(discounted) 
U
n
ce
rt
a
in
ty
 
EVPI £17 £331,143 £3.08 million 
EVPPI (Parameters I) £4.07 £81,521 £759,500 
EVPPI (Parameters II) £0.01 £295 £2,753 
EVSI (Study I) £4.07 £81,526 £759,543 
EVSI (Study II) £0 £0 £0 
Im
pl
em
en
ta
tio
n
 
EVPIM  £304 £6.08 million £56.7 million 
rEVPI £49 £984,191 £9.17 million 
rEVPPI (Parameters I+II)  £7.8 £156,352 £1.46 million 
EVSIM (Study I)  £8.2 £164,236 £409,598 
EVSIM (Study II)  £12.3 £246,354 £424,172 
Bo
th
 
EVP £321 £6.41 million £60 million 
EVR (Study I) £12.27 £245,762 £1.17 million 
EVR (Study II) £12.3 £246,354 £424,172 
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Figure 4. Dynamic EVP and post-research residual EVPs 
  
 
 
When the timing of research is considered and the results of the research only become available after decision 
making, as could be the case in a Recommendation with Research decision, the values of the EVSIM are 
lower than the values of the EVSIM when research reported before the recommendation decision (Table 5). 
The newly calculated EVSIM values, however, are still larger than the values obtained from the static 
analysis. The fact that the decrease is considerable is explained by the relatively large difference between 
diffusion curves especially in the first few periods and the discounting that would result in greater importance 
being placed on the periods in the near future. Figure 6 shows the reductions in the EVP when the timing of 
research is accounted for. 
The implementation curves for the two studies and the kinks they exhibit at the time of reporting of the results 
compared with the (dotted) curves that could have been obtained if research reported now are presented in 
Figure 7. This illustrates that the time at which research reports could have a large effect on the EVSIM. For 
example, if research reported only after the ten year time horizon, the EVSIM would be zero. 
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 Table 5. EVSIM values at future reporting times 
 Per 
person 
Population per 
annum (20,000 
patients affected)  
Population over time 
horizon of 10 years 
(discounted) 
EVSIM (Study I)  £7.44 £148,800 £324,000 
EVSIM (Study II)  £9.73 £194,700 £335,000 
EVR (Study I) £11.51 £230,367 £1.08 million 
EVR (Study II) £9.70 £194,708 £335,249 
 
 
 
 
  
Figure 6. Dynamic EVP and post-research residual EVPs with timing of research 
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 Figure 7. Implementation curves with different research studies and reporting times 
 
 
Even when considering the timing of research, the EVRs of the different research studies have increased 
considerably with the dynamic analysis compared with the static analysis, making a recommendation with 
research decision more valuable than under the static analysis. Whether the value of research would cover the 
cost of these research studies would have to be assessed in further analyses, but it appears unlikely based on 
the presented results. 
 
Discussion and conclusion of the Dynamic Expected Value of Research analysis 
This work has demonstrated an extension to the expected value of information and implementation framework 
presented by Fenwick et al. (2008) that facilitates assessing research studies for their value in terms of both 
the reduction in uncertainty and the improvement in implementation. This study has gone beyond other 
applications of the expected value of implementation (Walker et al., 2014, Hoomans et al., 2009), by 
considering the effect of research on implementation and by quantifying the dynamics of implementation 
using diffusion theory and incorporating the timing of research.  
These extensions have proven significant in this case study. In the comparison of the static and dynamic 
analyses, it was shown that dynamic results differed considerably from the results of the static analysis. This 
means that incorporating implementation dynamics and the timing of research are essential when assessing the 
expected value of implementation measures and research.  
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The expected value of research may be larger than thought when only the EVPI is calculated because research 
may also have value in terms of increasing implementation through the rEVPI, which was identified as 
important by Fenwick et al. (2008). Its importance was proven in this case study, in which the impact of 
research on the value of implementation was much greater than the impact on the value of reduced decision 
uncertainty. In practical terms this could have a substantive effect on the conclusion of a value of research 
recommendation.  
The analysis of the dynamic EVPIM could be a tool for decision-makers to recognise the impact of low 
implementation and the potential value of implementation measures. Although at present the reimbursement 
authority in the UK, NICE, does not have the mandate to decide on implementation measures other than 
recommending the collection of data (NICE, 2013), the dynamic expected value of research that was proposed 
here can support a Recommendation with Research (RwR) decision, which is one type of managed entry 
agreements used by reimbursement authorities and manufacturers to agree on a process of recommending a 
new technology (Walker et al., 2012). With this analysis, research efforts cannot only be directed to yield the 
largest EVSI but also to maximise implementation, thus optimising the EVR. Of course, a RwR decision 
requires other preceding analyses which were outlined by Walker et al. (2012), such as assessing the 
reversibility of any decision, or checking for similar studies being currently undertaken in other jurisdictions. 
When implementation is not expected to be an issue, this approach is irrelevant in the decision-making 
process of a reimbursement authority. There may be some health technologies that are generally less prone to 
low implementation. To our knowledge, there is no standard way of identifying technologies with potentially 
low implementation, hinting at the need for a screening process that should precede any further analysis to 
identify future implementation levels. This screening process could entail qualitative interviews with relevant 
stakeholders and ideally an elicitation exercise to quantify implementation. 
The strength of this study is the incorporation of implementation dynamics, the estimation of which is based 
on the theory of diffusion of innovative technologies (Rogers, 2003) and an adaptation of the Bass model of 
new product growth (Bass, 1969), using elicitation of expert opinions. This method, only requiring the 
elicitation of 3 parameters for each diffusion curve, enabled us to take the relationship between information 
and implementation into account. As such, it has the potential to make the assessment of implementation 
measures and the value of research more realistic, both in terms of the implementation that can be achieved 
and in terms of the expected implementation when doing nothing.  
This work should add transparency to decision-making processes by highlighting the cost of low 
implementation to the payer. It can also be used to facilitate initiatives to improve implementation by 
revealing the value of implementation measures. 
The proposed approach has been illustrated in a case study of a technology that is still in development. This is 
of relevance because technology assessments commonly occur before technology introduction and when there 
is still funding for research. We have argued that addressing the issue of potentially low implementation at the 
time of technology assessments would save the health care system resources and therefore provide health 
gains for patients. 
The applicability of the EVR framework and the use of implementation dynamics within technology 
appraisals are restricted to those health technologies that may experience low implementation, which means 
that this knowledge is a prerequisite for this analysis. If this framework was adopted by a decision-maker, 
there would be additional resources required for the trial simulation and in quantifying implementation levels 
with and without the use of implementation measures. 
Another limitation is the assumption that technologies B and C have an equal share over those patients that do 
not receive technology A. It is possible that one of the alternative technologies B and C may benefit from the 
implementation of A and push the other technology out completely. Better estimates of the implementation of 
B and C, conditional on implementation of A, would thus be desirable. Related to this, changes in short-term 
expected net benefit when the technology switch occurs that were explored in a study by Van de Wetering et 
al. (2012) could result in reduced EVSIM levels. This was ignored here but could be incorporated in the 
present framework. 
The calculations of the expected value of implementation and the realisable EVPI were deterministic and did 
not take uncertainty surrounding implementation dynamics into account. An extension to this work could 
therefore include making the mentioned analyses probabilistic; that is, simulating the possible outcomes for 
the expected value of research when the parameters informing the implementation dynamics curves are varied. 
This is possible, given that uncertainty surrounding implementation dynamics was elicited. 
It may be beneficial to test the dynamic EVR analysis in other exemplar technology appraisals to obtain a 
better overview of potential outcomes, uses of the framework and processes required to establish this analysis 
within technology assessments.  
In conclusion, implementation dynamics can be applied in the Expected Value of Research analysis to assess 
the value of research studies in terms of reducing uncertainty and improving implementation, thus 
complementing the currently used analyses in health technology assessments. Importantly, if dynamics of 
implementation are considered, then it makes sense to draw on diffusion theory and its related research. 
Elicitation of expert opinions can be used to estimate the relationship between information and 
implementation. When calculating the EVR, the timing of research is potentially important. 
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Technical Appendix 
The Expected Value of Information: 
 ܧܸܲܫ ൌ ॱఏ݉ܽݔௗܰܤሺ݀ǡ ߠሻ െ ݉ܽݔௗॱఏܰܤሺ݀ǡ ߠሻ (1)  
Where ܰܤሺ݀ǡ ߠሻ is the expected net monetary benefit of technology d given the uncertain model input 
parametersߠ. 
 
The Expected Value of Implementation: 
 ܧܸܲܫܯ ൌ  ݉ܽݔௗॱఏܰܤሺ݀ǡ ߠሻ െ ෍ ߩௗ஼ॱఏܰܤሺ݀ǡ ߠሻ஽ௗୀଵ  (2)  
Where ߩௗ஼ is the probability of implementing technology d with current information. 
 
The Expected Value of Perfection: 
 ܧܸܲ ൌ  ॱఏ݉ܽݔௗܰܤሺ݀ǡ ߠሻ െ ෍ ߩௗ஼ॱఏܰܤሺ݀ǡ ߠሻ஽ௗୀଵ  (3)  
The realisable Expected Value of Information: 
 ݎܧܸܲܫ ൌ ॱఏ ෍ ߩௗ௉ܰܤሺ݀ǡ ߠሻ஽ௗୀଵ െ ෍ ߩௗ஼ॱఏܰܤሺ݀ǡ ߠሻ஽ௗୀଵ  (4)  
Where ߩௗ௉ is the probability of implementing technology d with perfect information. 
 
Alternatively, the rEVPI can be written as: 
 ݎܧܸܲܫ ൌ ܧܸܲܫܯ௣௥௘ିோ െ ܧܸܲܫܯ௣௢௦௧ିோ (5)  
 
The EVPIM is the sum of the rEVPI and the post-research EVPIM: 
 ܧܸܲܫܯ ൌ ݎܧܸܲܫ ൅ ܧܸܲܫܯ௣௢௦௧ିோ (6)  
 
The Expected Value of Sample Information: 
 ܧܸܵܫ ൌ  ॱ௑ൣ݉ܽݔௗॱఏȁ௑ሼܰܤሺ݀ȁߠሻሽ൧ െ ݉ܽݔௗॱ௑ൣॱఏȁ௑ሼܰܤሺ݀ǡ ߠሻሽ൧ (7)  
Where data X are informative for the input parameters. 
 
The Expected Value of Research: 
 ܧܸܴ ൌ ܧܸܵܫ ൅ ܧܸܵܫܯሺܴ݁ݏ݁ܽݎ݄ܿሻ (8)  
 
The dynamic realisable Expected Value of Information: 
 ݎܧܸܲܫௗ௬௡തതതതതതതതതതതതത ൌ  ?ܶ෍ ൥ॱఏ ෍ ߩ௧ǡௗ௉ ܰܤሺ݀ǡ ߠሻ஽ௗୀଵ െ ෍ ߩ௧ǡௗ஼ ॱఏܰܤሺ݀ǡ ߠሻ஽ௗୀଵ ൩்௧ୀଵ  (9)  
Where W «7 is the time period up to the defined time horizon T, in years.  
 
The dynamic EVPIM, rEVPPI and EVSIM:  
 ܧܸܲܫܯௗ௬௡തതതതതതതതതതതതതത ൌ  ?ܶ෍ ൥݉ܽݔௗॱఏܰܤሺ݀ǡ ߠሻ െ ෍ ߩ௧ǡௗ஼ ॱఏܰܤሺ݀ǡ ߠሻ஽ௗୀଵ ൩்௧ୀଵ  (10)  
 
 ݎܧܸܲܲܫௗ௬௡തതതതതതതതതതതതതതത ൌ   ?ܶ෍ ൥ॱఏ೔ ൭෍ ߩௗఏ೔ॱఏష೔ȁఏ೔ሼܰܤሺ݀ǡ ߠ௜ȁߠି௜ሻሽ஽ௗୀଵ ൱்௧ୀଵെ ෍ ߩ௧ǡௗ஼ ॱఏܰܤሺ݀ǡ ߠሻ஽ௗୀଵ ൩ (11)  
 ܧܸܵܫܯௗ௬௡തതതതതതതതതതതതതത ൌ   ?ܶ෍ ൥෍ ߩ௧ǡௗூெॱఏܰܤሺ݀ǡ ߠሻ஽ௗୀଵ െ ෍ ߩ௧ǡௗ஼ ॱఏܰܤሺ݀ǡ ߠሻ஽ௗୀଵ ൩்௧ୀଵ  (12)  
 
 
 
The dynamic EVPI at population level and over the time horizon:  
  
ܲǤ ܧܸܲܫௗ௬௡തതതതതതതതതതതതതത ൌ  ?ܶ෍ ߩ௧ǡௗొాǤౣ౗౮௉ ߨ்௧ୀଵ ܧܸܲܫௗ௬௡തതതതതതതതതതതሺ ? ൅ ݎሻ௧  (13)  
With ߨ representing the affected population per year and ߩ௧ǡௗొాǤౣ౗౮௉  the implementation at perfect information 
of the technology with the maximum expected net benefit in year t. 
 
The dynamic EVSIM at population level and over the time horizon:  
 ܲǤ ܧܸܵܫܯௗ௬௡തതതതതതതതതതതതതതതതത ൌ  ?ܶ෍ ߩ௧ǡௗొాǤౣ౗౮௉ ߨ்௧ୀଵ ܧܸܵܫܯௗ௬௡തതതതതതതതതതതതതതሺ ? ൅ ݎሻ௧  (14)  
 
 
